Spyre Therapeutics, Inc. (SYRE)
79.04
-1.06
(-1.32%)
USD |
NASDAQ |
Oct 16, 13:27
Spyre Therapeutics SG&A Expense (TTM) : 55.54M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 55.54M |
| March 31, 2026 | 51.20M |
| December 31, 2025 | 47.91M |
| September 30, 2025 | 46.15M |
| June 30, 2025 | 45.15M |
| March 31, 2025 | 44.87M |
| December 31, 2024 | 45.78M |
| September 30, 2024 | 49.08M |
| June 30, 2024 | 47.01M |
| March 31, 2024 | 47.56M |
| December 31, 2023 | 39.95M |
| September 30, 2023 | 30.95M |
| June 30, 2023 | 29.32M |
| March 31, 2023 | 24.93M |
| December 31, 2022 | 28.53M |
| September 30, 2022 | 30.76M |
| June 30, 2022 | 30.64M |
| March 31, 2022 | 29.79M |
| December 31, 2021 | 27.32M |
| September 30, 2021 | 27.04M |
| June 30, 2021 | 25.87M |
| March 31, 2021 | 23.74M |
| December 31, 2020 | 21.84M |
| September 30, 2020 | 19.17M |
| Date | Value |
|---|---|
| June 30, 2020 | 17.80M |
| March 31, 2020 | 16.93M |
| December 31, 2019 | 15.73M |
| September 30, 2019 | 14.90M |
| June 30, 2019 | 13.90M |
| March 31, 2019 | 13.02M |
| December 31, 2018 | 12.63M |
| September 30, 2018 | 11.44M |
| June 30, 2018 | 11.15M |
| March 31, 2018 | 10.59M |
| December 31, 2017 | 10.06M |
| September 30, 2017 | 9.797M |
| June 30, 2017 | 8.842M |
| March 31, 2017 | 8.926M |
| December 31, 2016 | 8.392M |
| September 30, 2016 | 7.959M |
| June 30, 2016 | 7.255M |
| March 31, 2016 | 6.93M |
| December 31, 2015 | 5.947M |
| September 30, 2015 | 4.959M |
| June 30, 2015 | 3.598M |
| March 31, 2015 | 1.475M |
| December 31, 2014 | 0.628M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| AbbVie, Inc. | 14.67B |
| Incyte Corp. | 1.399B |
| SELLAS Life Sciences Group, Inc. | 14.87M |
| Relay Therapeutics, Inc. | 50.06M |
| ACADIA Pharmaceuticals, Inc. | 620.29M |